๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Erratum to: Evidence that prokineticin receptor 2 exists as a dimer in vivo

โœ Scribed by Sara Marsango; Maria Carmela Bonaccorsi di Patti; Donatella Barra; Rossella Miele

Publisher
Springer
Year
2011
Tongue
English
Weight
93 KB
Volume
68
Category
Article
ISSN
1420-682X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Blocking of interleukin 2 (IL 2) binding
Blocking of interleukin 2 (IL 2) binding to the IL 2 receptor is not required for the in vivo action of anti-IL 2 receptor monoclonal antibody (mAb). I. The production, characterization and in vivo properties of a new mouse anti-rat IL 2 receptor mAb that reacts with an epitope different to the one that binds to IL 2 and the mAb ART-18
โœ Athanasia Mouzaki; Hans-Dieter Volk; Hisao Osawa; Tibor Diamantstein ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 727 KB

A mouse anti-rat interleukin 2 (IL 2) receptor (IL 2R) monoclonal antibody (mAb), ART-65, has been developed. As shown by fluorescence-activated cell sorter analysis and immunoprecipitation studies, ART-65 recognizes in a species-specific manner the same molecule as does ART-18, a mAb which has been

Sustained-release (+)-PHNO [MK-458 (HPMC
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation
โœ Dr. Jesse M. Cedarbaum; Mary Clark; Linda H. Toy; Alison Green-Parsons ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 683 KB

## Abstract 4โ€โ€Propylโ€9โ€hydroxynaphthoxazine, or MKโ€458 (HPMC), a selective, nonergot D2 agonist administered orally twice a day in sustainedโ€release form, was studied as adjunctive therapy with carbidopaโ€levodopa (Sinemet) in 12 Parkinson's disease patients with motor response fluctuations. The do